HK1078784A1 - Therapeutic treatment - Google Patents

Therapeutic treatment

Info

Publication number
HK1078784A1
HK1078784A1 HK05110831A HK05110831A HK1078784A1 HK 1078784 A1 HK1078784 A1 HK 1078784A1 HK 05110831 A HK05110831 A HK 05110831A HK 05110831 A HK05110831 A HK 05110831A HK 1078784 A1 HK1078784 A1 HK 1078784A1
Authority
HK
Hong Kong
Prior art keywords
therapeutic treatment
therapeutic
treatment
Prior art date
Application number
HK05110831A
Other languages
English (en)
Inventor
Francis Thomas Boyle
Jon Owen Curwen
Neil James Gallagher
Ursula Joy Hancox
Andrew Mark Hughes
Donna Johnstone
Sian Tomiko Taylor
David William Tonge
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of HK1078784A1 publication Critical patent/HK1078784A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK05110831A 2002-10-12 2005-11-28 Therapeutic treatment HK1078784A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0223854.1A GB0223854D0 (en) 2002-10-12 2002-10-12 Therapeutic treatment
PCT/GB2003/004347 WO2004035057A1 (en) 2002-10-12 2003-10-07 Therapeutic treatment

Publications (1)

Publication Number Publication Date
HK1078784A1 true HK1078784A1 (en) 2006-03-24

Family

ID=9945876

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05110831A HK1078784A1 (en) 2002-10-12 2005-11-28 Therapeutic treatment

Country Status (30)

Country Link
US (1) US20060122180A1 (no)
EP (1) EP1553950B1 (no)
JP (1) JP2006510605A (no)
KR (1) KR20050056238A (no)
CN (1) CN100342853C (no)
AR (1) AR041595A1 (no)
AT (1) ATE369136T1 (no)
AU (1) AU2003269259B2 (no)
BR (1) BR0315140A (no)
CA (1) CA2501959A1 (no)
CY (1) CY1107605T1 (no)
DE (1) DE60315490T2 (no)
DK (1) DK1553950T3 (no)
ES (1) ES2289316T3 (no)
GB (1) GB0223854D0 (no)
HK (1) HK1078784A1 (no)
IS (1) IS2473B (no)
MX (1) MXPA05003808A (no)
MY (1) MY135441A (no)
NO (1) NO20051658L (no)
NZ (1) NZ539137A (no)
PL (1) PL375584A1 (no)
PT (1) PT1553950E (no)
RU (1) RU2005114487A (no)
SA (1) SA04240502B1 (no)
TW (1) TW200412971A (no)
UA (1) UA82492C2 (no)
UY (1) UY28017A1 (no)
WO (1) WO2004035057A1 (no)
ZA (1) ZA200502874B (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
GB0219660D0 (en) 2002-08-23 2002-10-02 Astrazeneca Ab Therapeutic use
WO2004100991A1 (en) * 2003-05-15 2004-11-25 Universite Catholique De Louvain Use of endothelin-1 antagonists for improving cancer therapy
GB0320806D0 (en) * 2003-09-05 2003-10-08 Astrazeneca Ab Therapeutic treatment
GB0403744D0 (en) 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
GB0425854D0 (en) * 2004-11-25 2004-12-29 Astrazeneca Ab Therapeutic treatment
PT2209501E (pt) * 2007-10-12 2012-02-03 Astrazeneca Ab Composição de zibotentan contendo manitol e celulose microcristalina
SG178828A1 (en) * 2009-08-10 2012-04-27 Univ Texas Treatment of brain metastases with inhibitors of endothelin receptors in combination with a cytotoxic chemotherapy agent
AU2020314971A1 (en) * 2019-07-17 2022-02-10 Enb Therapeutics, Inc. Treatment of urothelial and kidney cancers by use of endothelin B receptor antagonists
AU2022297082B2 (en) 2021-06-22 2024-04-18 Alchemedicine, Inc. Compound, endothelin A receptor antagonist and pharmaceutical composition

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5514691A (en) * 1993-05-20 1996-05-07 Immunopharmaceutics, Inc. N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5464853A (en) * 1993-05-20 1995-11-07 Immunopharmaceutics, Inc. N-(5-isoxazolyl)biphenylsulfonamides, N-(3-isoxazolyl)biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
AU661533B2 (en) * 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
US6063911A (en) * 1993-12-01 2000-05-16 Marine Polymer Technologies, Inc. Methods and compositions for treatment of cell proliferative disorders
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
UA58494C2 (uk) * 1995-06-07 2003-08-15 Зенека Лімітед Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну
US5780435A (en) * 1995-12-15 1998-07-14 Praecis Pharmaceuticals Incorporated Methods for treating prostate cancer with LHRH-R antagonists
ATE295839T1 (de) * 1998-04-29 2005-06-15 Osi Pharm Inc N-(3-ethinylphenylamino)-6,7-bis(2-methoxyethox )-4-chinazolinamin-mesylat-anhydrat und -monohydrat
US6355678B1 (en) * 1998-06-29 2002-03-12 Parker Hughes Institute Inhibitors of the EGF-receptor tyrosine kinase and methods for their use
GB0008368D0 (en) * 2000-04-06 2000-05-24 Astrazeneca Ab Combination product
US20020055457A1 (en) * 2000-08-07 2002-05-09 Janus Todd J. Methods of treating cancer and the pain associated therewith using endothelin antagonists
US20030092757A1 (en) * 2001-04-11 2003-05-15 Amitabh Singh Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer
DE10155076A1 (de) * 2001-11-09 2003-05-22 Merck Patent Gmbh Verwendung von Endothelin-Rezeptor-Antagonisten zur Behandlung von Tumorerkrankungen

Also Published As

Publication number Publication date
EP1553950B1 (en) 2007-08-08
DE60315490D1 (de) 2007-09-20
AU2003269259B2 (en) 2007-03-15
BR0315140A (pt) 2005-08-16
DE60315490T2 (de) 2008-05-08
UA82492C2 (uk) 2008-04-25
JP2006510605A (ja) 2006-03-30
CA2501959A1 (en) 2004-04-29
DK1553950T3 (da) 2007-10-15
IS2473B (is) 2008-12-15
ZA200502874B (en) 2006-02-22
NZ539137A (en) 2008-01-31
MXPA05003808A (es) 2005-06-08
GB0223854D0 (en) 2002-11-20
PL375584A1 (en) 2005-11-28
PT1553950E (pt) 2007-09-26
NO20051658L (no) 2005-05-06
TW200412971A (en) 2004-08-01
UY28017A1 (es) 2004-04-30
ATE369136T1 (de) 2007-08-15
CN100342853C (zh) 2007-10-17
KR20050056238A (ko) 2005-06-14
RU2005114487A (ru) 2006-02-10
SA04240502B1 (ar) 2008-09-14
US20060122180A1 (en) 2006-06-08
CY1107605T1 (el) 2013-03-13
AU2003269259A1 (en) 2004-05-04
MY135441A (en) 2008-04-30
ES2289316T3 (es) 2008-02-01
WO2004035057A1 (en) 2004-04-29
AR041595A1 (es) 2005-05-26
EP1553950A1 (en) 2005-07-20
IS7825A (is) 2005-04-26
CN1703224A (zh) 2005-11-30

Similar Documents

Publication Publication Date Title
GB0201850D0 (en) Therapeutic treatment
GB0216321D0 (en) Therapeutic treatment
GB0316912D0 (en) Therapeutic treatment
GB0320806D0 (en) Therapeutic treatment
GB0201674D0 (en) Medical treatment
HK1078784A1 (en) Therapeutic treatment
GB0223367D0 (en) Therapeutic treatment
SI1545256T1 (sl) Naprava za terapevtsko zdravljenje
GB0218879D0 (en) Medical treatment
GB0219660D0 (en) Therapeutic use
GB0210464D0 (en) Therapeutic treatment
GB0329275D0 (en) Therapeutic treatment
GB0307863D0 (en) Therapeutic treatment
GB0313772D0 (en) Therapeutic treatment
GB0211297D0 (en) Pain treatment
SI1553950T1 (sl) Terapevtsko zdravljenje
GB0207139D0 (en) Novel therapeutic treatment
GB0207138D0 (en) Novel therapeutic treatment
GB0321236D0 (en) Therapeutic treatment
GB0321233D0 (en) Therapeutic treatment
GB0321235D0 (en) Therapeutic treatment
GB0300881D0 (en) Therapeutic treatment
GB0318552D0 (en) Therapeutic treatment
GB0321649D0 (en) Therapeutic treatment
GB0321650D0 (en) Therapeutic treatment

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20111007